What management is recommended for an asymptomatic 44-year-old male with controlled hypertension, a broadband ultrasound attenuation (BUA) of 507, elevated total cholesterol (5.8 mmol/L), and elevated triglycerides (2.25 mmol/L)?

Management Recommendation

This asymptomatic 44-year-old male with controlled hypertension, elevated total cholesterol (5.8 mmol/L), and borderline-high triglycerides (2.25 mmol/L) requires cardiovascular risk assessment followed by initiation of statin therapy if his 10-year ASCVD risk is ≥7.5%, along with aggressive lifestyle modifications targeting his triglyceride levels.

Cardiovascular Risk Assessment

First, calculate this patient's 10-year ASCVD risk using a validated risk calculator (PREVENT equations or Pooled Cohort Equations). At age 44 with hypertension on medication, his baseline risk is already elevated 1. The presence of borderline-high triglycerides (2.25 mmol/L = 199 mg/dL) should be considered as a risk-enhancing factor when making treatment decisions 1.

Key point: His triglyceride level of 2.25 mmol/L (199 mg/dL) falls into the "borderline-high" category (150-199 mg/dL), which warrants comprehensive cardiovascular risk assessment 2.

Lipid Management Strategy

Primary Intervention: Lifestyle Modifications

Implement therapeutic lifestyle changes immediately 1, 3:

• Diet modification: Reduce refined carbohydrates, limit alcohol intake, adopt a heart-healthy diet pattern
• Weight management: Screen for metabolic syndrome components (central obesity, insulin resistance)
• Regular aerobic exercise: At least 150 minutes weekly of moderate-intensity activity
• Smoking cessation: If applicable

Secondary Causes Evaluation

Screen for and address secondary causes of hypertriglyceridemia 1:

• Diabetes mellitus: Check HbA1c and fasting glucose
• Hypothyroidism: Measure TSH
• Chronic kidney disease: Check creatinine and eGFR
• Liver disease: Assess liver function tests
• Medication review: Identify drugs that may elevate triglycerides (beta-blockers, thiazide diuretics, corticosteroids)

Statin Therapy Decision

If his 10-year ASCVD risk is ≥7.5%, initiate moderate-to-high intensity statin therapy 1. The 2018 AHA/ACC guideline specifically states that in adults 40-75 years with moderate hypertriglyceridemia and ASCVD risk ≥7.5%, persistently elevated triglycerides should favor statin initiation or intensification 1.

Recommended statin regimens:

• Atorvastatin 20-40 mg daily, OR
• Rosuvastatin 10-20 mg daily

Important caveat: If the patient is of East Asian descent, start with lower rosuvastatin doses (5 mg) per FDA recommendations 1.

LDL-Cholesterol Target

While the total cholesterol is 5.8 mmol/L (224 mg/dL), you need to obtain a complete lipid panel including:

• LDL-cholesterol (primary target)
• HDL-cholesterol
• Non-HDL-cholesterol (secondary target = total cholesterol minus HDL-cholesterol)

Target LDL-C levels based on risk:

• If ASCVD risk ≥7.5%: Aim for LDL-C reduction of ≥50% from baseline
• Calculate non-HDL-cholesterol goal (LDL-C goal + 30 mg/dL)

Triglyceride-Specific Management

Since his triglycerides are borderline-high (2.25 mmol/L = 199 mg/dL) but not severely elevated, the primary focus should be on lifestyle modifications and statin therapy 1, 3.

Do NOT initiate fibrate therapy at this level - fibrates are reserved for:

• Severe hypertriglyceridemia (≥500 mg/dL or ≥5.6 mmol/L)
• Risk of acute pancreatitis (triglycerides ≥1000 mg/dL)

Consider omega-3 fatty acid supplementation (over-the-counter fish oil 2-4 grams daily) as an adjunct to lifestyle changes 1.

Follow-Up Strategy

Reassess in 4-12 weeks after initiating statin therapy:

• Repeat lipid panel to evaluate response
• Check liver enzymes (ALT) at baseline and after statin initiation
• Assess for statin-associated muscle symptoms
• Reinforce lifestyle modifications

If triglycerides remain persistently elevated after addressing lifestyle factors and optimizing statin therapy, and if his ASCVD risk remains ≥7.5%, this persistent elevation should be considered a factor favoring intensification of lipid-lowering therapy 1.

Critical Pitfalls to Avoid

1. Don't treat triglycerides in isolation - always assess comprehensive cardiovascular risk 4
2. Don't add fibrates for borderline-high triglycerides - they're indicated only for severe hypertriglyceridemia (≥500 mg/dL) 1
3. Don't overlook secondary causes - uncontrolled diabetes or hypothyroidism will sabotage lipid management 1
4. Don't forget that statins are first-line therapy - they address both LDL-cholesterol and provide modest triglyceride reduction 3

Additional Considerations

Given his controlled hypertension, ensure blood pressure remains at goal (<130/80 mmHg per current guidelines). The combination of hypertension and dyslipidemia significantly amplifies cardiovascular risk, making aggressive risk factor modification essential 5.

Consider coronary artery calcium (CAC) scoring if his ASCVD risk calculation falls in the borderline range (5-7.5%), as this can help refine treatment decisions 6. However, if his risk is clearly ≥7.5%, proceed directly with statin therapy without delay.